you you all Thank and us today. very joining for much, Pia, thank
As into XXXX HIF-X priority stage our highest we are launch development for casdatifan. inhibitor alpha heading is late program to our
belzutifan. X ENA know, clearly our late in key weeks best-in-class a line, demonstrating conviction in oral measure cas inhibitor, RCC improvement we at data from presented just every data efficacy our cas ARC-XX clear-cell you As we an session will be plenary in meeting. initial versus These study the evaluating ago, that analyze validates HIF-X alpha that
the only belzutifan alpha As market is you on know, HIF-X inhibitor the today.
X, from dataset. our go to highlights Slide So I'll and the recap let's
low expansion only progression cohort in XX% similarly in was the the primary XXX-milligram was First daily off, the cohort. XX-milligram expansion rate and of daily
mind not XXX-milligram are points of for of primary the and LITESPARK-XXX. and will DCR, XX-milligram fully in XX that Keep that observed in approximately what the change. half the fact, primary in only rate was rate, are disease the cohorts progression mature combined In control rate expansion patients was progression the and data
a huge really is this the molecule. difference So for
reported of we on a XX% XX% disease and confirmed X the therapy. and unconfirmed out ORR pending X stable ORR confirmation for with still multiple Second, responses patients XXX-milligram cohort also
cutoff, did patient As belzutifan on exception confirm.
The kinetics remained of provide data the response the one whose HIF-X of precedent actually every both response the cohorts not that treatment of inhibition. for alpha responder across data with with good
So this of additional responses months XX% within the treatment in of is Approximately important. each XX% of and an X X-month occurred ensuing occurred periods.
in to X our that for across cas out XX goes milligrams.
The that also XX improve and illustrate more is XXX could, in activity the both So cohorts. data mind, ORR Keep reality further follow-up and These months those ARC-XX extremely durable. demonstrated times data why likely XX should, respectively are and of months. months
that reached with XX months. the our not that median median data approved belzutifan PFS Recall its XXXX, median had a of been we benchmark. even which that As months exceed easily early to should report of was And X.X expect in PFS, upon follow-up. based cutoff, PFS
of this Given that will the another be important PFS source is endpoint, registration differentiation.
the approaching XX-week generated of heavily pretreated a with to LITESPARK-XXX. that also want in deepening responses relative that plot spider see duration of emphasize of patients were or I patient data and show past to multiple these treatment, Our population either you time.
Specifically, wouldn't approximately patients for XX% of in LITESPARK-XXX. ARC-XX ineligible -- the be enrolled
the very and confirmed almost data responder a XX% over a ORR progression and XX% despite pending cutoff, cohort, rate, XX% we months with the reported a primary XX-milligram median DCR the of impressive only confirmation, remarkable For one X XX%. at follow-up ORR unconfirmed just
One of the response. complete confirmed a was responders
spider can stable continued already disease, therapy extremely few plots. to XX% you threshold, nearly of with XX% and on that still Beyond close response again, the the in whom and the point, responders, a another including important patients are see
belzutifan the this We still XXX-milligram data present evolving cohorts show relative expect to additional the throughout will XXX-milligram data data a we plan Slide X, share that are once-daily median that plan cohorts. year. and set mature we including and have XXXX. more efficacy present to expansion While ARC-XX, cohorts now from we of the to from more come.
On PFS to year, XX-milligram the and differentiation tablet the there's we and is XXX-milligram demonstrating from to that ARC-XX to improve, clear early different next will that and continue X lot data be ORR initial in of Later data
that's another worth XX data. of So patients
cas which XX from X we part pre-Phase milligrams date, the drugs meeting cohort. maintained. cabo of cas to from the with present shared already safety of of our consistent milligrams been plus of expansion cabo initial To with data plan of our individual the the and and are safety also profiles the as intensity XXX dose We cohort, data this has FDA
we in enrollment. more ahead will the first of is the us, support initiation enthusiasm investigators, We opportunities the to evolution the it's that X important to updates set it's provide investigator Given our believe enrolled, of study term. the this important Phase additional to study importance near multiple you, considering data and important the PEAK-X. we're for study, towards the from and steam to data, rapid incredibly ARC-XX of ongoing the cohorts high, that's we've remain The full which
Now anti-TIGIT domvanalimab, let to our Fc-silent antibody. switch gears me
yesterday, evaluated from first-line chemotherapy PD-LX antibody, versus Just was that's SITC the anti-PD-X zim non-small our zimberelimab, Part released high our X dom ARC-XX cancer. cell plus in versus which abstract study, data lung of with
combination Slide that a STAR-XXX, both reasons exceeded generate XX, and that termination PFS conducted opportunity gave was from ORR, the to reminder, to us We conditions.
On a zim we on on under data our X Phase study now early study present monotherapy a for As an we zim set and terminated plus the show OS. summarize strategic chemo stud. But the abstract. dom focus
With for which XX.X of below median months detail, is to hazard far in points. in clinically discuss better both but the OS we ratio this studies not and PFS is are X benchmark X.XX, want important meaningfully achieved and reached OS, above monotherapy.
Dimitry than going these considered threshold For these PFS results I median anti-PD-X setting. data a contemporary dom-zim, meaningful for to make
non-small anti-TIGIT sets First as first-line cancer a antibodies TIGIT Dom relative late-stage in AstraZeneca's bispecific data data In development differentiated safety months, that adverse of rates Fc-enabled the Fc-enabled are growing reaffirm continue anti-PD-X anti-TIGIT for these Fc-enabled in gastric anti-TIGIT issues. to lung Combining off, see in few the important antibodies events AE Fc-silent to Fc-silent reports that have of and specifically are rates AstraZeneca cancer. profile cell look the X line discontinuations. that Interestingly, sets anti-PD-X with contrast, therapy X today, their treatment-related profile.
In and well and the the as last antibody. for first-line antibodies, of we alone. That's these antibody data to very recognition with own, chemotherapy absolutely to antibodies higher efficacy an both immune-related antibodies.
There only similar exacerbate clinical our of presented similar component seems
of that that at that earlier shared PD-LX last presented will point have gastric data that dom-zim presented I be both we to which compelling high year year this gastric the detail this we cancers. the and results data SITC, more ARC-XX and we lung non-small set, in with in in sets second The cancer X ASCO, in now EDGE potential cell lung data make the ARC-X at is supporting want
seen with our for the and from With we're anti-TIGIT survival with next and EDGE X in to in study, first continue benchmark potential studies, to health have PFS we $X year, the mature our study the studies. X we we For non-small a setting with to lung have gastric X preparing enrolled, X anti-TIGIT an study. first-line alone authorities. billion-plus settings actively believe and potential of the our we're a months setting. dom-zim.
In half for of to median pursuing, study, we PACIFIC-X lung gastric in to of with PFS cancer, we STAR-XXX a gastric be which readout months differentiated cancer. overall X latter first-line on to first-line showed in X cancer, fully XX in in this this the trials submission antibody opportunity.
In cancer is cell dom-zim first combination And our market the potentially present execute We meaningfully expect for Phase this STAR-XXX partnership Meanwhile, surpassed Stage AstraZeneca,
largest to number our of of continue We for the to our also for optimized dom-zim studies evaluate statistical all they're patients. analysis ensure addressing while success, but plans probability that
study a outcomes CDXX could Taiho's Phase expect this [ this to advance transformative the quemli PRISM-X, initiated where is in also plus a to selective quemli to That's metastatic year, our pancreatic patients.
Early for believe X inhibitor study cohorts we into executing non-small cell next continue cancer. We other with ] Japan. in We've a inhibitor, program, advance lung they're in AXL in the first-line highly opt-in our therapy dismal with cancer. pipeline. chemo. We first-line ABXXX, in evaluating disease be our And expansion programs to
and and enabled in highly and us with relationships $X.X funded Taiho to a multiple mid-XXXX, are advance programs of clinical billion they've With for investments all manner. runway readouts. and Our resource-efficient Gilead, cash AstraZeneca strong, aggressively comfortably we're into our in
the over the cas. our to market go to we it and Jen to turn plans results, for to like I'd discuss Before ARC-XX development opportunity
